Acumen Pharmaceuticals (ABOS)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	47.06 mm	47.06 mm	47.06 mm	47.06 mm	47.06 mm	47.06 mm
Cash burn (monthly)	(no burn)	(no burn)	8.84 mm	11.52 mm	10.16 mm	10.30 mm
Cash used (since last report)	n/a	n/a	20.48 mm	26.70 mm	23.55 mm	23.88 mm
Cash remaining	n/a	n/a	26.58 mm	20.37 mm	23.51 mm	23.18 mm
Runway (months of cash)	n/a	n/a	3.0	1.8	2.3	2.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ABOS institutional ownership history Ownership history

76.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	81	75	+8.0%
Opened positions	15	11	+36.4%
Closed positions	9	20	-55.0%
Increased positions	27	24	+12.5%
Reduced positions	19	21	-9.5%

13F shares	Current	Prev Q	Change
Total value	72.87 bn	105.27 bn	-30.8%
Total shares	46.19 mm	47.30 mm	-2.3%
Total puts	117.10 k	748.60 k	-84.4%
Total calls	37.40 k	57.70 k	-35.2%
Total put/call ratio	3.1	13.0	-75.9%

Largest owners	Shares	Value	Change
Ra Capital Management	14.93 mm	$25.68 bn	0.0%
Sands Capital Ventures	3.42 mm	$5.88 bn	0.0%
BEN Franklin Resources	3.27 mm	$5.63 bn	-7.8%
Paul B Manning	2.55 mm	$0.00	0.0%
BlackRock	2.37 mm	$4.08 bn	+1.7%
FMR	2.02 mm	$3.48 bn	-0.2%
Vanguard	1.94 mm	$3.34 bn	+0.3%
Rock Springs Capital Management	1.84 mm	$3.16 bn	-20.0%
Knollwood Investment Advisory	1.63 mm	$2.80 bn	0.0%
Millennium Management	1.34 mm	$2.31 bn	-26.7%

Largest transactions	Shares	Bought/sold	Change
JPM JPMorgan Chase & Co.	937.91 k	+874.84 k	+1387.2%
T. Rowe Price	13.62 k	-836.00 k	-98.4%
Millennium Management	1.34 mm	-490.01 k	-26.7%
Rock Springs Capital Management	1.84 mm	-461.14 k	-20.0%
Jane Street	30.74 k	-456.86 k	-93.7%
BEN Franklin Resources	3.27 mm	-275.44 k	-7.8%
TD Asset Management	0.00	-139.21 k	EXIT
UBS UBS	141.49 k	+118.74 k	+521.9%
ADAR1 Capital Management	94.29 k	+94.29 k	NEW
Group One Trading	28.85 k	-93.74 k	-76.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ABOS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Nov 25	George Golumbeski	Stock Option Common Stock	Grant	Acquire A	No	No	1.9	50,000	95.00 k	50,000
4 Jun 25	Derrell Porter	Common Stock	Grant	Acquire A	No	No	0	12,800	0.00	12,800
4 Jun 25	Derrell Porter	Stock Option Common Stock	Grant	Acquire A	No	No	1.07	19,500	20.87 k	19,500
4 Jun 25	Jeffrey L. Ives	Common Stock	Grant	Acquire A	No	No	0	12,800	0.00	12,800
4 Jun 25	Jeffrey L. Ives	Stock Option Common Stock	Grant	Acquire A	No	No	1.07	19,500	20.87 k	19,500
4 Jun 25	Nathan B Fountain	Common Stock	Grant	Acquire A	No	No	0	12,800	0.00	19,050
4 Jun 25	Nathan B Fountain	Stock Option Common Stock	Grant	Acquire A	No	No	1.07	19,500	20.87 k	19,500

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Acumen And JCR Pharma Collaborative Study Shows Improved Brain Distribution of AβO-Targeting Antibodies

2 Dec 25

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD),

B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8

18 Nov 25

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $9 to $8.

Earnings Scheduled For November 12, 2025

12 Nov 25

Preview: Acumen Pharmaceuticals's Earnings

11 Nov 25

12 Health Care Stocks Moving In Thursday's Intraday Session

25 Sep 25